Research
Hormonal
Intensive blood pressure control (targeting systolic BP < 120 mmHg) does not reduce fatal or nonfatal major cardiovascular events in patients with Type 2 Diabetes compared to standard control (< 140 mmHg) and increases adverse events.
If you have Type 2 Diabetes and high blood pressure, aiming for very low blood pressure (under 120 systolic) does not protect your heart more than standard targets (under 140) and may cause side effects like dizziness or kidney issues. Stick to standard guidelines unless your doctor specifies otherwise.
StrongRefutesHIGH confidence
the group with intensive BP control did not have a reduction in fatal and nonfatal major CV events as compared to the standard BP control group... In addition, the intensive BP group had increased adverse events including hypotension, syncope, bradycardia or arrhythmia, hyperkalemia, angioedema and renal failure
Why this rating
Based on ACCORD-BP trial.
Source
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Benjamin M Leon · World Journal of Diabetes · 2015
DOI 10.4239/wjd.v6.i13.1246
narrative_reviewCited 1,237×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive glycemic control (targeting HbA1c ≤ 6.5%) does not significantly reduce cardiovascular events or all-cause mortality in patients with Type 2 Diabetes compared to standard control, and may increase mortality risk.Strong
- Intensive glycemic control (targeting HbA1c ≤ 7%) significantly reduces cardiovascular events and microvascular complications in patients with Type 1 Diabetes.Strong
- Statins significantly reduce cardiovascular events, all-cause mortality, and stroke in patients with Type 2 Diabetes, regardless of baseline cholesterol levels.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →